HC Wainwright Reaffirms Buy Rating for Maze Therapeutics (NASDAQ:MAZE)

Key Points

• Maze Therapeutics (NASDAQ: MAZE) has had its "buy" rating reaffirmed by HC Wainwright with a target price of $50.00, suggesting a potential upside of 112.77% based on the last closing price.
• Other analysts have set varying ratings and target prices for Maze, with figures ranging from $17.00 to $37.00, reflecting a generally positive outlook on the stock.
• The company recently reported earnings of ($0.77) EPS, beating the consensus estimate of ($0.79) by $0.02, indicating some resilience in its financial performance.

HC Wainwright reaffirmed their buy rating on shares of Maze Therapeutics (NASDAQ:MAZE - Free Report) in a report released on Thursday morning,Benzinga reports. They currently have a $50.00 price objective on the stock.

Several other equities research analysts also recently commented on the stock. Guggenheim boosted their target price on shares of Maze Therapeutics from $19.00 to $34.00 and gave the company a "buy" rating in a research note on Monday, September 15th. BTIG Research boosted their price objective on Maze Therapeutics from $30.00 to $37.00 and gave the stock a "buy" rating in a report on Friday, September 12th. Wedbush assumed coverage on Maze Therapeutics in a research note on Tuesday, July 8th. They issued an "outperform" rating and a $17.00 price target for the company. Finally, Wall Street Zen raised Maze Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th. Two equities research analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $32.67.

Maze Therapeutics Trading Up 0.9%

MAZE stock traded up $0.21 during midday trading on Thursday, reaching $23.15. 184,083 shares of the company's stock traded hands, compared to its average volume of 280,555. The business has a 50-day moving average price of $16.15 and a two-hundred day moving average price of $12.68. Maze Therapeutics has a fifty-two week low of $6.71 and a fifty-two week high of $25.50.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.79) by $0.02.

Insider Transactions at Maze Therapeutics

In other Maze Therapeutics news, Director Richard H. Scheller sold 20,744 shares of the stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $22.37, for a total value of $464,043.28. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Institutional Trading of Maze Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. General Catalyst Group Management LLC acquired a new position in shares of Maze Therapeutics in the 1st quarter worth $11,405,000. Bessemer Group Inc. acquired a new stake in Maze Therapeutics during the first quarter valued at approximately $5,305,000. Bank of New York Mellon Corp acquired a new stake in Maze Therapeutics during the first quarter valued at approximately $190,000. New York State Common Retirement Fund acquired a new position in shares of Maze Therapeutics in the 1st quarter worth approximately $25,000. Finally, Alphabet Inc. acquired a new position in shares of Maze Therapeutics in the 1st quarter worth approximately $26,561,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.